发明申请
WO2017139623A1 COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS
审中-公开
ABCG2抑制剂与SACITUZUMAB GOVITECAN（IMMU-132）联合阻断TROP-2表达的肿瘤对SN-38的耐药性
- 专利标题： COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS
- 专利标题（中）： ABCG2抑制剂与SACITUZUMAB GOVITECAN（IMMU-132）联合阻断TROP-2表达的肿瘤对SN-38的耐药性
-
申请号： PCT/US2017/017435申请日： 2017-02-10
-
公开(公告)号： WO2017139623A1公开(公告)日： 2017-08-17
- 发明人: CHANG, Chien-Hsing , GOLDENBERG, David M.
- 申请人： IMMUNOMEDICS, INC.
- 申请人地址： 300 American Road Morris Plains, New Jersey 07950 US
- 专利权人： IMMUNOMEDICS, INC.
- 当前专利权人： IMMUNOMEDICS, INC.
- 当前专利权人地址： 300 American Road Morris Plains, New Jersey 07950 US
- 代理机构： NAKASHIMA, Richard, A.
- 优先权： US62/293,530 20160210; US62/329,788 20160429; US62/336,985 20160516
- 主分类号： A61K45/06
- IPC分类号： A61K45/06 ; A61K47/48 ; C07K16/30
摘要：
The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.
